Welcome to our dedicated page for ADMA Biologics news (Ticker: ADMA), a resource for investors and traders seeking the latest updates and insights on ADMA Biologics stock.
ADMA Biologics, Inc. (Nasdaq: ADMA) is an end-to-end commercial biopharmaceutical company dedicated to the development, manufacturing, and commercialization of specialty plasma-derived biologics. The company's core focus is on treating immunocompromised patients at risk of infection, particularly those with primary immune deficiency diseases (PIDD) and other infectious diseases. ADMA's mission is to deliver critical therapeutics to niche patient populations through its robust product portfolio.
The company's lead product, RI-002, has successfully completed a Phase III clinical trial for treating PIDD, meeting its primary endpoint. The Biologics License Application (BLA) for RI-002 was accepted by the U.S. Food and Drug Administration (FDA) on September 18, 2015, marking a significant milestone for ADMA. Additionally, the company has received numerous U.S. patents, including U.S. Patent 9,107,906, further solidifying its innovative approach to plasma-derived therapies.
ADMA's commercial product lineup includes three FDA-approved plasma-derived biologics:
- BIVIGAM® – Immune globulin intravenous for the treatment of primary humoral immunodeficiency (PI).
- ASCENIV™ – Immune globulin intravenous (human – slra 10% liquid), indicated for PI treatment.
- NABI-HB® – Hepatitis B immune globulin for enhanced immunity against the hepatitis B virus.
The company operates through two primary segments: ADMA BioManufacturing, which generates the majority of its revenue, and Plasma Collection Centers. ADMA BioCenters is responsible for collecting human plasma, a vital component for producing its therapeutic products. This network now includes multiple FDA-licensed collection centers across the United States.
ADMA has recently reported impressive financial milestones, including total revenues of $81.9 million for Q1 2024, a 44% year-over-year increase, and a Q1 2024 GAAP net income of $17.8 million, marking a significant turnaround. The company also reported first-time positive GAAP net income of $2.6 million in 3Q 2023, highlighting its profitable trajectory.
The company continues to innovate, leveraging technologies such as ADMAlytics™, an AI-driven platform aimed at optimizing production processes and improving operational efficiency. This platform is expected to provide substantial benefits across the company's supply chain and production operations.
ADMA's strategic growth initiatives include expanding its commercial product offerings, enhancing manufacturing yields, and advancing preclinical pipeline programs targeting S. pneumonia. The company has also secured a new $135 million credit facility to support its growth objectives further.
For more information about ADMA Biologics and its products, please visit the company's website at www.admabiologics.com.
ADMA Biologics reported strong second quarter 2022 results with total revenues of $33.9 million, a 90% year-over-year increase. Gross profit surged to $7.8 million, marking a 112% improvement from the previous quarter. The company narrowed net losses to $13.8 million, a 45% reduction from the first quarter. Full-year revenue guidance is set to exceed $130 million. Strategic expansions are ongoing, including plans for more FDA-licensed BioCenters. The company also anticipates achieving profitability by Q1 2024 with long-term revenue targets of up to $300 million.
ADMA Biologics, Inc. (Nasdaq: ADMA) will report its Q2 financial results for the period ended June 30, 2022, on August 10, 2022. The announcement includes a live conference call at 4:30 p.m. ET to discuss financial outcomes and company updates. ADMA specializes in manufacturing and marketing plasma-derived biologics, currently offering FDA-approved products for immunodeficient patients. The company operates a plasma fractionation facility in Boca Raton, Florida, and also runs FDA-approved plasma collection centers.
ADMA Biologics (Nasdaq: ADMA) announced its inclusion in the Russell 2000® Index, effective June 27, 2022, as per the preliminary list from FTSE Russell released on June 17, 2022. The Russell 2000® Index assesses the performance of small-cap stocks in the U.S. equity market and is a benchmark for numerous investment strategies, managing approximately $12 trillion in assets. ADMA specializes in plasma-derived biologics aimed at treating immunodeficient patients and has three FDA-approved products, including BIVIGAM® and ASCENIV™.
ADMA Biologics reported first quarter 2022 revenues of $29.1 million, an 81% increase from the previous year. This growth has led the company to increase its full-year revenue guidance to $130 million or more. The gross margin improved to 13%, despite a $6.7 million one-time charge due to debt refinancing. ADMA expects continued operational efficiency and profitability, aiming for $250 million in revenue by 2024 and potential margins of 40-50%. The company ended Q1 with $70 million in cash and plans to draw an additional $25 million in non-dilutive funds.
ADMA Biologics, Inc. (Nasdaq: ADMA) will announce its Q1 2022 financial results on May 11, 2022, after market close. A live conference call is scheduled for the same day at 4:30 p.m. ET to discuss these results and other company updates. ADMA specializes in plasma-derived biologics aimed at immunodeficient patients and currently markets three FDA-approved products: ASCENIV™, BIVIGAM®, and NABI-HB®. The company operates from its Boca Raton, Florida facility and maintains FDA approval for its processes and products.
ADMA Biologics, Inc. (Nasdaq: ADMA) announced a poster presentation and Key Opinion Leader symposium on respiratory viral infections (RVIs) and ASCENIV, its FDA-approved IVIG product. The poster, presented by Dr. Kevin Rosenbach, highlights ASCENIV’s real-world outcomes for patients with primary immunodeficiency (PI) suffering from chronic respiratory infections. Additionally, discussions led by Dr. Jolan Walter and Dr. Dareen Siri will focus on the management of RVIs and clinical use of ASCENIV. ASCENIV is designed for treating primary humoral immunodeficiency, leveraging a unique plasma donor screening methodology.
ADMA Biologics has announced FDA approval to extend the shelf life of its ASCENIV and BIVIGAM immune globulin products from 24 to 36 months. This approval applies to all sizes and production scales, enhancing inventory management for healthcare providers. CEO Adam Grossman stated this milestone reflects improvements in ADMA’s manufacturing processes and supports a stronger market position amid fluctuating demand. The updated products are now available to U.S. healthcare providers, potentially increasing market penetration and addressing patient needs more effectively.
ADMA Biologics reported total revenues of approximately $81 million for full year 2021, a 92% increase from 2020. The company's gross profitability was attributed to a higher-margin product mix and increased market penetration. ADMA completed a $175 million debt refinancing with Hayfin Capital Management, extending its interest-only period to March 2027, significantly improving its cash position. For 2022, ADMA expects revenues to exceed $125 million, signifying a projected growth rate of over 50% compared to 2021.
ADMA Biologics has announced it will report its financial results for Q4 2021 and the full year on March 24, 2022, after U.S. markets close. The company, which specializes in plasma-derived biologics for immunodeficient patients, will host a conference call on the same day at 4:30 p.m. ET to discuss these results. ADMA currently markets three FDA-approved products: ASCENIV™, BIVIGAM®, and NABI-HB®. It operates an FDA-licensed facility in Boca Raton, FL, and is dedicated to treating and preventing infectious diseases.
ADMA Biologics has received FDA approval for its fifth plasma collection facility in Conyers, Georgia, enhancing its aim for plasma supply self-sufficiency. This facility, operational since Q3 2021, can now collect human source plasma for manufacturing. With a target of having 10 FDA-approved centers by year-end 2023, ADMA is strengthening its position in the U.S. immunoglobulin market. The new center boasts advanced collection technology and a focus on donor comfort and safety, with a staff of 50 at full capacity.
FAQ
What is the current stock price of ADMA Biologics (ADMA)?
What is the market cap of ADMA Biologics (ADMA)?
What are the primary products offered by ADMA Biologics?
What is ADMA Biologics' mission?
How has ADMA Biologics performed financially recently?
What recent technological advancements has ADMA made?
What is RI-002, and why is it significant for ADMA?
What are ADMA Biologics' primary business segments?
How does ADMA Biologics plan to sustain its growth?
What makes ASCENIV™ unique?
Where can I find more information about ADMA Biologics?
What recent financial achievements has ADMA reported?
